Literature DB >> 9048192

Immune responses to adenoviral vectors during gene transfer in the brain.

K Kajiwara1, A P Byrnes, H M Charlton, M J Wood, K J Wood.   

Abstract

We have investigated the immune response to E1-deleted adenovirus vectors encoding the lacZ gene introduced into the brains of adult mice. Injection of these nonreplicating vectors caused a marked inflammatory response in the brain as assessed by immunocytochemistry and flow cytometry of leukocytes. Infiltrating leukocytes were detectable within 2 days of injection and reached a maximum by 9 days. Thereafter, the number of infiltrating cells decreased, but a small number persisted in the brain until day 60. Between 2 and 4 days after injection, the percentage of CD8+ cells detectable increased whereas the percentage of CD4+ cells present in the infiltrating population did not significantly increase until day 6, peaking on day 15. Activated CD25+ T cells were detectable between days 6 and 15. beta-Galactosidase (beta-Gal), the product of the lacZ gene encoded by the vector, was also detected, both at the injection site in the striatum and also in the substantia nigra. Expression peaked between 4 and 6 days but a small number of beta-Gal+ cells was still seen at 60 days after injection. This study demonstrates that a quantitative analysis of the immune responses caused by a nonreplicating adenovirus vector is possible in the brain. E1-deleted adenoviral vectors trigger a strong inflammatory response in the brain, but this immune response is not sufficient to eliminate completely expression of genes encoded by the adenoviral construct.

Entities:  

Mesh:

Year:  1997        PMID: 9048192     DOI: 10.1089/hum.1997.8.3-253

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  17 in total

1.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.

Authors:  C E Thomas; G Schiedner; S Kochanek; M G Castro; P R Löwenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Adenoviral and adeno-associated viral transfer of genes to the peripheral nervous system.

Authors:  M Glatzel; E Flechsig; B Navarro; M A Klein; J C Paterna; H Büeler; A Aguzzi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 4.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

5.  Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.

Authors:  Carlos Barcia; Christian Gerdes; Wei-Dong Xiong; Clare E Thomas; Chunyan Liu; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein
Journal:  Neuron Glia Biol       Date:  2006-11

6.  One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.

Authors:  Carlos Barcia; Maximiliano Jimenez-Dalmaroni; Kurt M Kroeger; Mariana Puntel; Alison J Rapaport; Daniel Larocque; Gwendalyn D King; Stephen A Johnson; Chunyan Liu; Weidong Xiong; Marianela Candolfi; Sonali Mondkar; Philip Ng; Donna Palmer; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2007-09-25       Impact factor: 11.454

7.  Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor.

Authors:  Jun Morioka; Koji Kajiwara; Koichi Yoshikawa; Makoto Ideguchi; Tetsuya Uchida; Yoshinori Ohmoto; Michiyasu Suzuki
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

Review 8.  Treatment of Parkinson's disease : what's on the horizon?

Authors:  Stacy S Wu; Steven J Frucht
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences.

Authors:  Qianhong Li; Yiru Guo; Wei Tan; Adam B Stein; Buddhadeb Dawn; Wen-Jian Wu; Xiaoping Zhu; Xiaoqin Lu; Xiaoming Xu; Tariq Siddiqui; Sumit Tiwari; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-19       Impact factor: 4.733

Review 10.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.